A biomarker can vary with cycle stage without being ready to guide an individual's fertility decisions. This observational study explored whether kisspeptin showed such a pattern. Primary study
How the evidence was collected
Fifteen volunteers with regular cycles were followed through one cycle with serum and urine measurements. Additional outpatient samples provided a separate cross-sectional component. The researchers reported stage-related kisspeptin changes and an association between serum kisspeptin and estradiol. They proposed a possible role as a pre-ovulation marker. No kisspeptin treatment was administered to establish those associations. Primary report
Our appraisal: preserve the sampling design
Repeated observations within one person can describe a trajectory. Samples from different people at different stages answer a different question. Combining the two sources without distinguishing them can make the longitudinal evidence seem larger than it is.
Multiple samples also do not create multiple independent participants. Analysis should account for within-person dependence and explain how cycle stage was assigned. A calendar-day pattern may not translate directly to people with different cycle lengths or irregular cycles.
An association with estradiol is not proof that kisspeptin independently improves prediction. A useful clinical marker must add information beyond what is already available, using a defined decision threshold and a suitable reference for ovulation timing.
Urine and serum results need separate analytical validation. Agreement in general direction does not establish that they can share one cutoff, unit interpretation, or collection schedule. Dilution and specimen-handling conditions are relevant questions for urinary measurements.
This paper contributes an exploratory physiological observation. It does not validate a home ovulation test, establish contraceptive reliability, or show that administering kisspeptin changes fertility. Full review should inspect assay specificity, timing definitions, participant selection, and external validation before turning a group pattern into individual prediction.
Frequently asked questions
Was there a longitudinal component?
Yes, in 15 volunteers.
Were additional outpatient samples also studied?
Yes.
Are cross-sectional samples repeated cycles in one person?
No.
Was kisspeptin administered as treatment?
No.
Does correlation establish added predictive value?
No.
Can serum and urine automatically share a cutoff?
No.
What remains necessary for a practical test?
Analytical and prospective clinical validation with explicit decision rules.